For other uses, see Sinopharm COVID-19 vaccine.
Pharmaceutical compound
 A vial of the BBIBP-CorV COVID-19 vaccine | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | Zhong'aikewei (Chinese: 众爱可维), Hayat-Vax |
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
.svg){kind=small}
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, resulting in the two different acronyms BBIBP and BIBP for the same vaccine). It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine (Vero Cell), not to be confused with the similar product name of CoronaVac.
Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group). In December 2020, the UAE previously announced interim results showing 86% efficacy.
While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. The BIBP vaccine could be transported and stored at normal refrigerated temperatures.
The vaccine is being used in vaccination campaigns by certain countries in Asia, Africa, South America, and Europe. Sinopharm expects to produce one billion doses of the vaccine in 2021. By May, Sinopharm had supplied 200 million doses.
On 7 May 2021, the World Health Organization approved the BIBP vaccine for use in COVAX. Sinopharm has signed purchase agreements for 170 million doses from COVAX.
The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.
Medical uses
The vaccine is given by intramuscular injection into the deltoid muscle. The initial course consists of two doses, and there is no evidence that a third booster dose is needed. The World Health Organization (WHO) recommends an interval of 3 to 4 weeks between doses.
Effectiveness
A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. Effectiveness is generally expected to slowly decrease over time.
Real-world test-negative analysis in Bahrain (based on 14 days post 2nd dose) indicated a vaccine effectiveness of 90% (95% CI, 88–91%) for adults aged 18–59, and 91% (87–94%) for those 60 year old or older. While confident in its overall efficacy, WHO experts expressed very low confidence in their current ability to determine the safety of the BIBP vaccine for people with comorbidities, pregnant women, and the elderly as they were under-represented in the studies.
In April 2021, a study by the Abu Dhabi Public Health Centre found the vaccine was 93% effective in preventing hospitalization and 95% effective against admission to intensive care. The study found no deaths related to COVID-19 in patients who received both doses. It was unknown how many people were included in the research.
On 1 July, the Ministry of Health of Argentina reported the vaccine reduced deaths by 62% after the first dose and by 84% after the second dose.
On 22 July, Peru's National Institute of Health reported the vaccine reduced deaths by 94% after analyzing data from 361,000 people.
On 13 August, a study with 400,000 health workers in Peru from February to June 2021, during a wave mostly caused by the Lambda and Gamma variants, found a vaccine effectiveness of 50% (49–52%) against infection and 94% (91–96%) against death after two doses. With a single dose, the effectiveness was 17% (15–20%) against infections and 46% (30–59%) against death.
On 24 August, preliminary results from a non-randomized study of one million people in Bahrain, of whom 569,054 received the BIBP vaccine, found that the vaccine continued to reduce infection, hospitalization, and death when the Delta variant became dominant, though not as effectively as Pfizer–BioNTech, Oxford–AstraZeneca and Sputnik V.
| Doses | Severity of illness | Delta | Alpha |
|---|---|---|---|
| 1 | Symptomatic | Not reported | Not reported |
| Hospitalization | Not reported | Not reported | |
| 2 | Asymptomatic | Not reported | 69% (67–70%) |
| Symptomatic | Not reported | Not reported | |
| Hospitalization | Not reported | Not reported | |
| Death | Not reported | 88% (86–89%) |
Efficacy
In December 2020, UAE's Ministry of Health and Prevention previously announced interim analysis showing the vaccine to have a 86% efficacy against COVID-19 infection and nearly 100% efficacy in preventing moderate and severe cases.
On 7 May 2021, the World Health Organization reported a vaccine efficacy of 79% (95% CI, 66–88%) against symptomatic disease and 79% (26–94%) against hospitalization.
In 26 May, peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed the vaccine 74% (61–82%) effective against cases including asymptomatic and symptomatic infections, 78% (95% CI, 65–86%) effective against symptomatic cases, and nearly 100% against severe cases (0 cases in vaccinated group, 2 cases in placebo group). 12,726 people received the vaccine and 12,737 people received the placebo in these trials.
As of 1 July, six of the 71 COVID-19 deaths in Seychelles were among the fully vaccinated people. Only one of the six was fully vaccinated by the BIBP vaccine, the remaining five had been fully vaccinated by Covishield, which was mainly reserved for people aged 60 years or more.
Variants
In February, lab studies of twelve serum samples taken from recipients of BBBP-CorV and ZF2001 retained neutralizing activity against the Beta variant although with weaker activity than against the original virus. For the BIBP vaccine, geometric mean titers declined by 1.6-fold, from 110.9 to 70.9, which was less than antisera from mRNA vaccine recipients with a 6-folds decrease. Preliminary clinical data from Novavax and Johnson & Johnson also showed they were less effective in preventing COVID-19 in South Africa, where the new variant is widespread.
In June, a pre-print study with 282 recipients of the vaccine in Sri Lanka showed that:
- 95% seroconverted following 2 doses, a similar rate seen in natural infection, with significantly lower seroconversion for >60 year-olds (93%) compared to 20-39 year-olds (99%)
- 81% had ACE2 receptor blocking antibodies capable of naturalizing the virus at 6 weeks, with the antibody titres at a level also similar to natural infection
- the antibody levels against Delta and Beta were at similar levels seen in natural infection, although much lower against Alpha
- there was a 1.38-fold reduction in antibody titres against Delta compared to the original strain, in contrast with 10-fold reduction against Beta
- the vaccine also induced T cell and memory B cell responses, although at lower magnitudes than some other vaccines
Manufacturing
As an inactivated vaccine like CoronaVac and Covaxin, the BIBP vaccine uses a more traditional technology that is similar to the inactivated polio vaccine. Initially, a sample of SARS-CoV-2 strain 19nCoV-CDC-Tan-HB02 (HB02) from China capable of rapid multiplication was chosen. Then, it was used to grow large quantities of the virus using vero cells. From then on, the viruses are soaked in beta-propiolactone, which deactivates them by binding to their genes, while leaving other viral particles intact. The resulting inactivated viruses are then mixed with the adjuvant aluminium hydroxide.
Sinopharm's Chairman Yang Xioyun has said the company could produce one billion doses in 2021.
In March 2021, Sinopharm and Abu Dhabi G42 announced plans to produce up to 200 million doses annually in the UAE at a new plant to become operational in 2021. The vaccine will be branded Hayat-Vax.
In December 2020, Egypt announced an agreement between Sinopharm and Egypt's VACSERA for the vaccine to be manufactured locally.
In March 2021, Serbia announced plans to produce 24 million doses of the BIBP vaccine annually starting in October.
In April 2021, Bangladesh approved local production of the BIBP vaccine.
In July 2021, Morocco's Société Thérapeutique Marocaine announced it would produce 5 million doses a month.
In November 2021, Sinopharm announced that it will build a sterile bottling plant in Singapore to enhance the distribution of the vaccine.
History
Clinical trials
Main article: COVID-19 vaccinePhases I and II
In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed by Sinopharm's Beijing Institute of Biological Products (BIBP) and the Wuhan Institute of Biological Products (WIBP). Both vaccines are chemically inactivated whole virus vaccines for COVID-19.
On 15 October, the Beijing Institute of Biological Products published results of its Phase I (192 adults) and Phase II (448 adults) clinical studies for the BIBP vaccine, showing it to be safe and well-tolerated at all tested doses in two age groups. Antibodies were elicited against SARS-CoV-2 in all vaccine recipients on day 42. These trials included individuals older than 60.
The vaccine may have characteristics favorable for vaccinating people in the developing world. While mRNA vaccines, such as the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of +90%, mRNA vaccines present distribution challenges for some nations, as some may require deep-freeze facilities and trucks. By contrast, the BIBP vaccine can be transported and stored at normal refrigeration temperatures. While Pfizer and Moderna are among developers relying on novel mRNA technology, manufacturers have decades of experience with the inactivated virus technology Sinopharm is using.
Phase III
In July 2020, Sinopharm began trials with 31,000 volunteers in the UAE in collaboration with G42 Healthcare, an Abu Dhabi-based company. In June 2021, Sinopharm began Phase III trials for children and adolescents aged 3–17 with 1,800 volunteers.
In September 2020, Sinopharm began trials in Casablanca and Rabat on 600 people. In September, Egypt started trials with 6,000 people.
In August, Sinopharm began trials in Bahrain with 6,000 people, later increased to 7,700 people. Also in August, Jordan began trials with 500 people.
In September, Peru began trials with 6,000 people which later expanded to 12,000 people. On 26 January, a volunteer in the placebo group of the trials had died from COVID-19 related pneumonia.
In September, Argentina began trials with 3,000 people.
In Pakistan, University of Karachi conducted a trial with 3,000 volunteers.
Authorizations
| |||
In China, Sinopharm obtained an EUA in July 2020. On 30 December 2020, China's National Medical Products Administration approved the BIBP vaccine for general use. In July 2021, China approved the EUA for children and adolescents aged 3–17.
In September 2020, UAE approved for emergency use authorization. In December 2020, UAE approved for full authorization. In August 2021, UAE approved the EUA for children and adolescents aged 3–17.
On 3 November 2020, Bahrain granted emergency use authorization for frontline workers. In December 2020, Bahrain approved the vaccine.
On 7 May 2021, the World Health Organization added the vaccine to the list of vaccines authorized for emergency use for COVID-19 Vaccines Global Access (COVAX).
In May 2021, Zambia approved use of the vaccine.
In June 2021, Philippines approved the BIBP vaccine for emergency use.
On 5 May 2021, EMA's human medicines committee (CHMP) has started a rolling review of the vaccine. The EU applicant for this medicine is the Italian company Life'On S.r.l.
Society and culture
Economics
By May, Sinopharm had supplied 200 million doses across all countries. In July, Sinopharm signed advanced purchase agreements with GAVI to supply COVAX 60 million doses in the third quarter of 2021 and up to a total of 170 million doses by the first half of 2022.
Asia
On 10 June, Afghanistan received a donation of 700,000 doses of the BIBP vaccine from China.
In July, Armenia approved the purchase of doses of the BIBP vaccine.
In April 2021, Bangladesh approved emergency use and had received 7 million doses by August. The country will purchase 60 million doses.
In February 2021, Brunei received the first batch of the vaccine donated by China, which has been approved for emergency use.
In February 2021, Cambodia granted emergency use authorization and started the vaccination campaign on 10 February. By July the country had received 5.2 million doses.
In April 2021, Indonesia approved emergency use. In May, a donation of 500,000 doses from the UAE arrived. By July, 7.5 million out of 15 million doses had arrived for a private vaccination program called "Gotong Royong", where companies could arrange a free COVID-19 vaccine rollout for their employees.
In February 2021, Iran approved emergency use and received 650,000 doses by 15 April of the same year, including 400,000 dose donation from Red Cross Society of China. Spokesperson of the Food and Drug Administration (Iran): What is offered and consumed from Sinopharm vaccine in Iran is its main platform and is licensed for emergency use by the World Health Organization.
In January 2021, Iraq approved emergency use. On 2 March, the first 50,000 dose arrived as a donation from China, with the Health Ministry indicating intention to purchase further 2 million doses.
In January 2021, Jordan approved emergency use, By July 1.37 million people had received their first dose and 833,000 people had received their second.
In April 2021, Kazakhstan approved emergency use of the vaccine, for which it had ordered 1 million doses.
In March 2021, Kyrgyzstan received a donation of 150,000 doses from China and began vaccinations on 29 March. The country later purchased 1.25 million doses which arrived in August.
In January 2021, Laos began vaccinating healthcare workers in Vientiane and received another 300,000 doses in early February.
In April 2021, Lebanon received a donation of 90,000 doses from China after granting emergency use authorization on 2 March.
In February 2021, Macau received the first 100,000 doses of 400,000 doses.
In March 2021, Maldives granted emergency approval for use. 100,000 doses were received on 25 March out of a total of 200,000 Chinese-donated doses.
By May 2021, Mongolia had received 4 million doses, with 300,000 doses as a donation from China. On 10 March, Governor of Ulaanbaatar D. Sumiyabazar and Deputy Prime Minister S. Amarsaikhan received the first doses.
In February 2021, Nepal approved the vaccine for emergency use. On 12 July, AP reported that China had donated 1.8 million doses, and was selling 4 million doses to Nepal.
In January 2021, Pakistan approved the vaccine for emergency use and began a vaccination campaign on 2 February. The country has purchased up to 23 million doses and received 6 million doses by July, including 1 million doses as a donation from China.
In March 2021, Palestine received 100,000 doses donated by China.
In April 2021, Philippines president Rodrigo Duterte received the vaccine after the food and drug regulator approved compassionate use of 10,000 doses for his security team.
In July 2021, Singapore began importing the vaccine under the Special Access Route framework.
In April 2021, Syria received 150,000 dose donated by China.
In March 2021, Sri Lanka approved emergency use. The country ordered 14 million doses on top of 1.1 million doses previously donated by China.
In April 2021, Turkmenistan began vaccinating school teachers and medical personnel with the Sinopharm vaccine.
On 14 September 2020, the United Arab Emirates approved the vaccine for front-line workers following interim Phase III trials. In December, the country registered the BIBP vaccine after it reviewed the results of the interim analysis. In March, a small number of people who have reduced immunity against diseases, chronic illnesses, or belong to high-risk groups have been given a third booster dose. In May, due to concerns about effectiveness, Bahrain planned to give a third booster dose to some groups at risk, and the United Arab Emirates extended its third booster dose to anyone who had received the second dose more than six months ago.
In June 2021, Thailand received one million doses.
In June 2021, Vietnam received a donation of 500,000 doses from China and later licensed importing of 5 million more doses.
On 11 August 2021 Philippines received 100,000 doses from United Arab Emirates, also will received 1,000,000 doses from China on 21 August.
Africa
In February, Algeria received a donation of 200,000 doses from China.
In March, Angola received a donation of 200,000 doses from China.
In April, Cameroon took delivery of 200,000 donated doses from China.
In January, Egypt approved use of the vaccine and had purchased 20 million doses, of which 1.5 million had arrived by April. President Abdel Fattah el-Sisi announced a vaccination campaign starting 24 January.
In March, Ethiopia received a donation of 300,000 doses from China.
In February, Equatorial Guinea received a Chinese donation of 100,000 doses which arrived on 10 February. The country began vaccinations on 15 February.
In March, Gabon received a Chinese donation of 100,000 doses which was the second vaccine approved for use in the country.
In May, Kenya announced plans to buy the vaccine.
In August, Libya received 2 million doses of the vaccine.
Morocco has ordered 40.5 million doses, of which 8.5 million had been delivered by May. Morocco had granted emergency use approval on 23 January.
In March, Mauritania received a donation of 50,000 doses from China and started its vaccination campaign on 26 March.
In April, Mauritius received a donation of 100,000 doses from China and ordered an additional 500,000 doses.
In February, Mozambique received a donation of 200,000 doses from China and planned to start vaccinations on 8 March.
In March, Namibia received a donation of 100,000 doses from China and announced the start of vaccinations in the Khomas and Erongo regions.
In March, Niger received a donation of 400,000 doses from China and began vaccinations on 27 March.
In February, Senegal received 200,000 doses that it purchased and began vaccinating health workers on 22 February.
In February, Sierra Leone received a donation of 200,000 doses from China. It was approved for emergency use and vaccinations began on 15 March.
In January, Seychelles began administering vaccinations with 50,000 doses it had received as a gift from the UAE.
In April, Somalia received a donation of 200,000 doses from China and started vaccinations with the vaccine on 14 April.
In March, Sudan received a donation of 250,000 doses from China.
In March, Republic of the Congo received 100,000 Chinese-donated doses with vaccinations prioritizing the medically vulnerable and those over 50.
In February, Zimbabwe purchased 600,000 doses on top of 200,000 doses donated by China, and started vaccinations on 18 February. Zimbabwe purchased an additional 1.2 million doses.
Europe
In February, Belarus received a donation of 100,000 doses from China and began using the vaccine on 15 March.
In July, Bosnia and Herzegovina ordered 500,000 doses.
In May, Georgia began vaccinations with the BIBP vaccine and received 1 million doses by July.
In January, Hungary became first member of the European Union to approve the BIBP vaccine, signing a deal for 5 million doses. Prime Minister Viktor Orbán was vaccinated with the BIBP vaccine on 28 February. 5.2 million doses were delivered to Hungary by May, fulfilling the contract.
In March, Moldova received 2,000 doses donated by the UAE which will be used to vaccinate doctors starting on 22 March.
In May, Montenegro received 200,000 doses, which was used to launch the vaccination campaign starting 4 May.
In April, North Macedonia received the first 200,000 of 800,000 doses which arrived from Serbia which was used in the vaccination campaign starting 4 May.
On 19 January, Serbia started vaccinations with the BIBP vaccine and was the first country in Europe to approve the vaccine. By April, Serbia has received 2.5 million doses. In March, Serbia had signed an agreement for an additional 2 million doses.
North America
In February, the Dominican Republic ordered 768,000 doses of the BIBP vaccine.
In March, Dominica received 20,000 donated doses of the BIBP vaccine from China which it began using in its vaccination campaign on 4 March.
In March, Mexico announced it would order 12 million doses of the BIBP vaccine pending approval by its health regulator, which was granted in August.
In May, Trinidad and Tobago received a donation of 100,000 doses from China. Another 200,000 and 800,000 doses were purchased and arrived 14 June and 13 July, respectively; bringing total doses of the BIBP vaccine received to 1.1 million.
In April, Barbados announced it would receive 30,000 doses of Chinese donated the BIBP vaccine, according to Prime Minister Mia Mottley.
Oceania
In April, Solomon Islands received a donation of 50,000 doses from China.
In May, Papua New Guinea approved use of 200,000 Chinese donated doses, which arrived on 1 July.
South America
In February, Argentina authorized emergency use of the BIBP vaccine. Eligibility was expanded to include people older than 60 on 25 March. By 4 June million doses had arrived and 6 million more were ordered.
In February, Bolivia started its vaccination campaign with the BIBP vaccine. In June, Bolivia purchased 6 million doses in addition to 2.7 million doses it had already received.
In March, Guyana received a donation of 20,000 doses from China and later purchased another 100,000 doses. Vaccinations started with elderly and healthcare workers.
In January, Peru purchased 38 million doses of the BIBP vaccine. Peru granted emergency approval on 27 January and started vaccinations on 9 February.
In March, Venezuela granted approval for the vaccine and received a donation of 500,000 doses from China on 2 March.
Controversies
See also: VacunagateIn February 2021, it was revealed that former Peruvian President Martín Vizcarra and other senior politicians were vaccinated in November 2020 before the vaccines were made available to health professionals and the public. They were vaccinated with extra doses that were brought in for the Phase III trials being conducted by Cayetano Heredia University in Lima with 12,000 volunteers.
In May 2021, Philippine President Rodrigo Duterte apologized for taking the BIBP vaccine which was not approved at the time. In response, Duterte said China should in the future only send CoronaVac, a separate vaccine which was approved in the Philippines at the time. Duterte said he only got the vaccine under a compassionate use clause, on recommendation from his doctor to get vaccinated. Later in June, the BIBP vaccine was approved for emergency use.
References
- "Covax Facility" (in Portuguese). Federal government of Brazil. Brazilian Health Regulatory Agency. 25 June 2021. Retrieved 20 November 2021.
- ^ Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X (January 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
- ^ "The Sinopharm COVID-19 vaccine: What you need to know". World Health Organization. 10 May 2021. Retrieved 5 July 2021.
- Nguyen S (5 June 2021). "Coronavirus: Vietnam approves Sinopharm's vaccine, but will people take it?". South China Morning Post. Retrieved 5 July 2021.
- Lahiri T, Li J (16 June 2021). "What we now know about the efficacy of China's Covid-19 vaccines". Quartz. Retrieved 5 July 2021.
- "WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations". World Health Organization. 7 May 2021. Retrieved 3 July 2021.
- "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. 19 November 2020. Retrieved 9 December 2020.
- ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
- ^ Corum J, Zimmer C (26 April 2021). "How the Sinopharm Vaccine Works". The New York Times. ISSN 0362-4331. Retrieved 29 April 2021.
- "WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations". World Health Organization. 7 May 2021. Retrieved 13 June 2021.
The Sinopharm product is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell).
- Chen W, Al Kaabi N (18 July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Archived from the original on 11 October 2020. Retrieved 13 June 2021.
- Yang Y. "A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above". Archived from the original on 14 September 2020. Retrieved 13 June 2021.
- "Sinovac's Coronavac™, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children" (Press release). Beijing: Bloomberg. Business Wire. 23 September 2020. Retrieved 13 June 2021.
- "A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Inactivated (Vero Cell) Vaccine in the Elderly 60–80 Years of Age, Coronovac ENCOV19 Study". registry.healthresearch.ph. Philippine Health Research Registry. Retrieved 13 June 2021.
- ^ Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X (26 May 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
- "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. 9 December 2020. Retrieved 13 December 2020.
- ^ "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 9 December 2020. Retrieved 9 December 2020.
- ^ Liu R (31 December 2020). "China gives its first COVID-19 vaccine approval to Sinopharm". Reuters. Retrieved 31 December 2020.
- Turak N (18 January 2021). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 21 January 2021.
- ^ "PM Imran kicks off Pakistan's Covid-19 vaccination drive". Dawn.com. 2 February 2021. Retrieved 3 February 2021.
- ^ "Sisi says Egypt to begin COVID-19 vaccinations on Sunday". Reuters. 24 January 2021. Retrieved 24 January 2021.
- Dumpis T (27 January 2021). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 28 January 2021.
- ^ "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 18 February 2021. Retrieved 20 February 2021.
- ^ "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. 25 March 2021. Retrieved 26 March 2021.
- ^ Aquino M (10 February 2021). "'The best shield': Peru launches inoculation drive with Sinopharm vaccine". Reuters. Retrieved 10 February 2021.
- ^ "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 28 February 2021.
- "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". Radio Free Europe/Radio Liberty. 20 January 2021. Retrieved 21 January 2021.
- "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 24 February 2021. Retrieved 26 February 2021.
- ^ "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 15 March 2021. Retrieved 16 March 2021.
- ^ "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 5 February 2021. Retrieved 28 February 2021.
- ^ "WHO approves Sinopharm vaccine in potential boost to COVAX pipeline". Reuters. 7 May 2021. Retrieved 14 May 2021.
- ^ "WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations" (Press release). World Health Organization (WHO). 7 May 2021. Retrieved 7 May 2021.
- ^ Taylor A (7 May 2021). "WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine". The Washington Post. Retrieved 7 May 2021.
- ^ "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 12 July 2021. Retrieved 13 July 2021.
- ^ Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm (Guidance). World Health Organization. 7 May 2021. WHO/2019-nCoV/vaccines/SAGE_recommendation/BIBP/2021.1.
- Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R (September 2020). "COVID-19 vaccine trials should seek worthwhile efficacy". Lancet. 396 (10253): 741–743. doi:10.1016/S0140-6736(20)31821-3. PMC 7832749. PMID 32861315.
WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
- Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP (May 2021). "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection". Nature Medicine. 27 (7): 1205–1211. doi:10.1038/s41591-021-01377-8. ISSN 1546-170X. PMID 34002089. S2CID 234769053.
- ^ Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine (PDF) (Presentation). World Health Organization. 29 April 2021. Retrieved 10 July 2021.
- Nebehay S (5 May 2021). "WHO experts voice "very low confidence" in some Sinopharm COVID-19 vaccine data". Reuters. Retrieved 18 May 2021.
- "Coronavirus: Sinopharm vaccine more than 90 per cent effective at preventing hospitalisation, Abu Dhabi study says". The National. 19 April 2021. Retrieved 21 April 2021.
- "Ministros de Salud de todo el país consensuaron redoblar esfuerzos para completar los esquemas de vacunación en mayores de 40 años" [Health ministers from all over the country agreed to redouble their efforts to complete vaccination schedules in people over 40 years of age] (in Spanish). Government of Argentina. Ministry of Health (Argentina). 1 July 2021. Retrieved 12 July 2021.
- Acosta S (22 July 2021). "INS: Vacuna de Sinopharm tiene efectividad de hasta 94% para reducir muerte por COVID-19". RPP (in Spanish). Retrieved 25 July 2021.
- "Peru study finds Sinopharm COVID vaccine 50.4% effective against infections". Reuters. 13 August 2021. Retrieved 15 September 2021.
- Silvia-Valencia J, Soto-Becerra P, Escobar-Agreda S, Fernández-Navarro M, Moscoso-Porras M, Solari L, Mayta-Tristan P (22 July 2021). Efectividad de la vacuna BBIBP-CorV para prevenir infección y muerte en personal de salud [Effectiveness of the BBIBP-CorV vaccine to prevent infection and death in health personnel] (Technical report) (in Spanish). Ministry of Health of Peru.
Tabla 4, figura 2
- AlQahtani M, Bhattacharyya S, Alawadi A, Mahmeed HA, Sayed J, Justman J, El-Sadr WM, Hidary J, Mukherjee S (24 August 2021). "Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain". Research Square (Preprint). doi:10.21203/rs.3.rs-828021/v1. S2CID 238713359.
Figures 1c, 2a and 4b
- Vokó Z, Kiss Z, Surján G, Surján O, Barcza Z, Pályi B, Formanek-Balku E, Molnár GA, Herczeg R, Gyenesei A, Miseta A (25 November 2021). "Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary - The HUN-VE study". Clinical Microbiology and Infection. 28 (3). Table 2. doi:10.1016/j.cmi.2021.11.011. ISSN 1198-743X. PMC 8612758. PMID 34838783.
- ^ "UAE says Sinopharm vaccine has 86% efficacy against COVID-19". Reuters. 9 December 2020. Retrieved 9 December 2020.
- "Six Fully Vaccinated People Died of Covid-19 in Most-Vaccinated Nation". Bloomberg.com. 11 July 2021. Retrieved 1 July 2021.
- ^ Liu R (3 February 2021). "Sinopharm's COVID-19 vaccine remained active against S.Africa variant, effect reduced - lab study". Reuters. Retrieved 29 March 2021.
- Huang B, Dai L, Wang H, Hu Z, Yang X, Tan W, Gao GF (2 February 2021). "Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines". bioRxiv: 2021.02.01.429069. doi:10.1101/2021.02.01.429069. S2CID 231834094.
- "Tests in Sri Lanka find Sinopharm vaccine very effective". Colombo Gazette. 20 July 2021. Retrieved 21 July 2021.
- Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Jayathilaka D, Gunesekara B, Tanussiya S, Kuruppu H, Ranasinghe T, Dayarathne S (19 July 2021). "Antibody and T cell responses to Sinopharm/BBIBP-CorV in naive and previously infected individuals in Sri Lanka". medRxiv 10.1101/2021.07.15.21260621.
- "Sinopharm vaccine effective against coronavirus Delta variant, study finds". The National. 21 July 2021. Archived from the original on 26 July 2021.
- Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X (August 2020). "Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2". Cell. 182 (3): 713–721.e9. doi:10.1016/j.cell.2020.06.008. PMC 7275151. PMID 32778225.
We therefore chose the HB02 strain for the further development of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV).
- "Sinopharm Covid-19 shot dubbed Hayat Vax for local rollout after UAE-China deal". Arabian Business. 29 March 2021.
- "Chinese COVID-19 vaccine effective: Egypt's MoH". EgyptToday. 13 December 2020. Retrieved 15 December 2020.
- "Serbia to produce 24 mln doses of China's Sinopharm vaccine annually - deputy PM". seenews.com. 17 March 2021. Retrieved 17 March 2021.
- "Bangladesh OKs local production of Chinese, Russian vaccines". www.aa.com.tr. Retrieved 29 April 2021.
- "Morocco's Sothema to produce China's Sinopharm vaccine". Reuters. 5 July 2021. Retrieved 6 July 2021.
- "与英诺医药合资1亿美元 国药子公司本地设厂灌封冠病疫苗 | 早报".
- Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X (September 2020). "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. 324 (10): 951–960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.
- ^ Maxwell C (14 September 2020). "Coronavirus: UAE authorises emergency use of vaccine for frontline workers". The National. Retrieved 14 September 2020.
- "Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 4 June 2021. Retrieved 9 June 2021.
- "Morocco orders R-Pharm Covid-19 vaccine | The North Africa Post". northafricapost.com. Retrieved 7 October 2020.
- "Chinese Clinical Trial Register (ChiCTR) - The world health organization international clinical trials registered organization registered platform". www.chictr.org.cn. Archived from the original on 31 December 2020. Retrieved 21 October 2020.
- "Egypt to start receiving volunteers for COVID-19 vaccine trials". Egypt Independent. 12 September 2020. Retrieved 21 September 2020.
- Manama TD (6 October 2020). "Vaccine trial continues | THE DAILY TRIBUNE | KINGDOM OF BAHRAIN". DT News. Retrieved 22 October 2020.
- ^ Barrington L (3 November 2020). "Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers". Reuters. Retrieved 3 November 2020.
- Liu R (5 September 2020). "China's CNBG, Sinovac find more countries to test coronavirus vaccines". Reuters. Retrieved 6 September 2020.
- "Jordan starts phase 3 trial of China's COVID-19 vaccine". Jordan Times. 30 August 2020. Retrieved 22 October 2020.
- "Third Phase of Human Trials for Coronavirus Vaccine Underway in Peru". Voice of America. 10 September 2020. Retrieved 11 September 2020.
- ^ "6,000 additional volunteers required for trials of Sinopharm's COVID-19 vaccine" (in Spanish). Andina. 17 October 2020. Retrieved 17 October 2020.
- Aquino M (27 January 2021). "Peru volunteer in Sinopharm vaccine trial dies of COVID-19 pneumonia, university says". Reuters. Retrieved 27 January 2021.
- "Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)". clinicaltrials.gov. Retrieved 28 September 2020.
- "Coronavirus vaccine should be available in Pakistan 'within 6-8 weeks'". www.geo.tv. Retrieved 14 November 2020.
- "Sinovac's coronavirus vaccine candidate approved for emergency use in China - source". Reuters. 29 August 2020. Retrieved 30 August 2020.
- "China approves Sinopharm vaccine for children, teenagers". The Star. 20 July 2021. Retrieved 15 August 2021.
- "UAE announces emergency approval for use of COVID-19 vaccine". Reuters. 15 September 2020. Retrieved 15 August 2021.
- Mansoor Z (9 December 2020). "UAE approves China's Sinopharm vaccine for use". Gulf Business. Retrieved 15 August 2021.
- Chik H (2 August 2021). "UAE approves use of China's Sinopharm vaccine for children aged 3 and over". South China Morning Post. Retrieved 15 August 2021.
- "Bahrain approves Chinese COVID-19 vaccine for use". ABC News. Retrieved 13 December 2020.
- Sachiti R. "Zambia to get Sinopharm COVID-19 vaccines". The Herald. Retrieved 21 May 2021.
- ^ Aguilar K (7 June 2021). "PH approves Sinopharm COVID-19 vaccine for emergency use". Philippine Daily Inquirer.
- "EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated". European Medicines Agency. 5 May 2021. Retrieved 5 January 2022.
- "Gavi signs agreements with Sinopharm and Sinovac for immediate supply to COVAX". www.gavi.org. Retrieved 13 July 2021.
- Nossiter A, Rahim N (10 June 2021). "Afghanistan gets 700,000 doses of a Chinese vaccine amid a Covid surge overwhelming Kabul". The New York Times.
- "Armenia to buy Sinopharm and Pfizer Covid-19 vaccines". arka.am. 29 July 2021. Retrieved 29 July 2021.
- Paul R (29 April 2021). "Bangladesh approves China's Sinopharm vaccine". Reuters. Retrieved 29 April 2021.
- "Maleque: Bangladesh will buy 60 million more Sinopharm vaccine doses from China". Dhaka Tribune. 7 August 2021. Retrieved 10 August 2021.
- "Vaccine donation from China arrives | The Star". www.thestar.com.my. Retrieved 12 February 2021.
- "COVID-19: Brunei to begin mass vaccination on April 3". The Scoop. 2 April 2021. Retrieved 3 April 2021.
- Rinith T (4 February 2021). "Health Ministry grants Emergency Use Authorization to China's Sinopharm vaccine". Khmer Times. Retrieved 4 February 2021.
- Kongnov T (9 February 2021). "Lt Gen Manet first to be inoculated today with the Sinopharm vaccine". Khmer Times. Retrieved 10 February 2021.
- "Cambodia calls for 21-day interval between first and second doses for Sinopharm and Sinovac Covid-19 vaccines - Khmer Times". 14 July 2021. Retrieved 30 July 2021.
- Rayda N. "Indonesia approves Sinopharm vaccine for private COVID-19 inoculation scheme". CNA. Retrieved 1 May 2021.
- "Indonesia Receives Gift of 500.000 Doses of Covid-19 Vaccines From the United Arab Emirates". Ministry of Foreign Affairs Republic of Indonesia. 1 May 2021.
- Sugiharto P, Raka A (30 July 2021). Nasution R (ed.). "1.5 million doses of Sinopharm vaccine arrive in Indonesia". Antara News. Retrieved 30 July 2021.
- "Iran Launches Phase Two of Mass Inoculation Campaign". Financial Tribune. 22 February 2021. Retrieved 23 February 2021.
- "400k doses of Sinopharm COVID-19 vaccine arrives in Iran: Official". IRNA English. 15 April 2021. Retrieved 15 April 2021.
- "Sinopharm used in Iran is the main platform". iribnews.ir. Retrieved 7 March 2022.
- Jangiz K. "Iraq approves the emergency use of two more COVID-19 vaccines". www.rudaw.net. Retrieved 21 January 2021.
- "Iraq receives first Covid vaccines, gift from China". France 24. 3 March 2021.
- "Jordan approves China's Sinopharm Covid vaccine". France 24. 9 January 2021. Retrieved 7 March 2021.
- "Sinopharm is most used vaccine in Jordan, Pfizer most coveted: study". en.royanews.tv. Retrieved 6 July 2021.
- Satubaldina A (30 April 2021). "Three Vaccines to Become Available to Kazakh Citizens". The Astana Times. Retrieved 1 May 2021.
- "Kazakhstan rolls out its own COVID-19 vaccine". Reuters. 27 April 2021. Retrieved 1 May 2021.
- Kharizov R (19 March 2021). "150,000 doses of Sinopharm coronavirus vaccine delivered to Kyrgyzstan". 24.kg. Retrieved 20 March 2021.
- "Kyrgyz health minister is vaccinated as rollout begins". Информационное Агентство Кабар. Retrieved 29 March 2021.
- "Kyrgyzstan buys further 1.25m doses of Chinese Sinopharm vaccine". akipress.com. Retrieved 10 August 2021.
- Thanabouasy P (27 January 2021). "Laos Begins Vaccinations for Over 600 Medical Workers". Laotian Times. Retrieved 27 January 2021.
- "Laos receives 300,000 vaccine doses from China". Bangkok Post. Bangkok Post Public Company Limited. Retrieved 10 February 2021.
- Lewis E (6 April 2021). "90,000 Sinopharm vaccines will join a trend in inoculations distributed outside the national vaccination plan". L'Orient Today. Retrieved 7 April 2021.
- "UAE sends Syria aid to help it fight spread of coronavirus". The Independent. 8 July 2021.
- Naharnet Newsdesk (1 March 2021). "Lebanon Authorizes Use of Chinese Vaccine Sinopharm". Naharnet. Retrieved 7 March 2021.
- Moura N (6 February 2021). "First Sinopharm Covid-19 vaccines to arrive today". Macau Business. Retrieved 7 February 2021.
- "MFDA approves Pfizer, Sinopharm Covid-19 vaccines for emergency use". raajje.mv. Retrieved 15 March 2021.
- "Maldives receives shipment of 100,000 Chinese Sinopharm doses". raajje.mv. Retrieved 25 March 2021.
- Stevenson A (20 May 2021). "Countries Are Scrambling for Vaccines. Mongolia Has Plenty". The New York Times. ISSN 0362-4331. Retrieved 25 May 2021.
- "Deputy PM and City Governor get the first dose of Sinopharm vaccine". MONTSAME News Agency. Retrieved 15 March 2021.
- "China's Shinopharm vaccine gets emergency use authorisation in Nepal". kathmandupost.comglish. Retrieved 19 February 2021.
- "US doses arrive as Nepal struggles to vaccinate population". AP News. 12 July 2021.
- Shahzad A (19 January 2021). "Pakistan approves Chinese Sinopharm COVID-19 vaccine for emergency use". Reuters. Retrieved 21 January 2021.
- "Pakistan to receive 5m doses of Sinovac on July 5". Daily Times. 3 July 2021. Retrieved 3 July 2021.
- "Over 20 million doses of Covid-19 vaccines transported from China to Pakistan". Daily Times. 7 July 2021. Retrieved 7 July 2021.
- "Palestinians receive 100,000 Sinopharm COVID-19 vaccines donated by China". Al Arabiya English. 29 March 2021. Retrieved 29 March 2021.
- "Philippines' Duterte receives first Sinopharm dose to encourage vaccine take-up". The Straits Times. 3 May 2021. Retrieved 3 May 2021.
- "11 Singapore private healthcare providers allowed to bring in Sinopharm COVID-19 vaccine". CNA. Retrieved 30 July 2021.
- "Syria gets donation of 150,000 COVID shots from China". Reuters. 24 April 2021. Retrieved 24 April 2021.
- "NMRA approves sinopharm vaccine for emergency use". Colombo Gazette. 19 March 2021. Retrieved 20 March 2021.
- "The Latest: Sri Lanka gets 2nd vaccine donation from China". ABC News. Retrieved 28 May 2021.
- "В Туркменистане от COVID бесплатно прививают китайской вакциной, российский "Спутник" можно купить". Радио Азатлык (in Russian). 7 April 2021. Retrieved 9 May 2021.
- Sircar N. "UAE Covid vaccine: Third dose to help those with weak immunity". Khaleej Times. Retrieved 19 March 2021.
- Nair A (18 May 2021). "UAE, Bahrain Plan Sinopharm Booster Shots Amid Efficacy Concerns". Bloomberg. Retrieved 26 May 2021.
- "Covid mixed doses study gets big response". Bangkok Post. 20 June 2021.
- "Thousands to get Sinopharm vaccine". Bangkok Post. 19 June 2021.
- "Vietnam receives 500,000 Sinopharm COVID-19 vaccine doses donation from China". CNA. Archived from the original on 20 June 2021. Retrieved 22 June 2021.
- "Vietnam licenses firm to import 5 mln doses of Sinopharm vaccine". Reuters. 9 July 2021. Retrieved 10 July 2021.
- Tomacruz S (11 August 2021). "UAE gives 100,000 Sinopharm vaccine doses to Philippines". Rappler. Retrieved 11 August 2021.
- "Algeria Receives 200,000 Coronavirus Jabs From China". www.barrons.com. AFP-Agence France Presse. Retrieved 26 February 2021.
- "Angola recebeu doação chinesa de 200 mil doses de vacinas Sinopharm". Notícias ao Minuto (in Portuguese). 25 March 2021. Retrieved 29 March 2021.
- Kouagheu J (11 April 2021). "Cameroon receives 200,000 doses of Sinopharm COVID-19 vaccine". Reuters. Retrieved 11 April 2021.
- "Cameroon receives 200,000 doses of COVID-19 vaccines from China". Milken Institute. 15 April 2021. Archived from the original on 5 August 2021. Retrieved 5 August 2021.
- "Egypt approves Chinese COVID vaccine, roll-out likely this month". www.aljazeera.com. Retrieved 3 January 2021.
- "Egypt to purchase 20 million doses of Sinopharm vaccine". Egypt Independent. 20 April 2021. Retrieved 21 April 2021.
- "Ethiopia gets 300,000 virus vaccine doses from China". www.aa.com.tr. Retrieved 30 March 2021.
- "Equatorial Guinea President receives 1st dose of Chinese COVID-19 vaccine". dailynewsegypt.com. 17 February 2021. Retrieved 10 March 2021.
- "Gabon receives 100,000 doses of Sinopharm's vaccine from China". Gabon 24. 12 March 2021. Archived from the original on 19 March 2021. Retrieved 13 March 2021.
- Muchangi J. "Kenya to buy Chinese Covid-19 vaccine". The Star. Retrieved 14 May 2021.
- "Libya gets 2 million Sinopharm doses with more expected". Africanews. 2 August 2021. Retrieved 10 August 2021.
- "COVID-19: Morocco receives new batch of over 2 million Sinopharm doses | The North Africa Post". northafricapost.com. Retrieved 23 May 2021.
- "Moroccan health ministry grants emergency approval to Sinopharm's Covid-19 vaccine". wam. 23 January 2021. Retrieved 27 January 2021.
- "Mauritania receives first Covid-19 vaccines from China". Africanews. 24 March 2021. Retrieved 25 March 2021.
- "Mauritania begins COVID-19 vaccination campaign". www.aa.com.tr. Retrieved 26 March 2021.
- "Mauritius receives 100,000 doses of Chinese vaccine". www.aa.com.tr. Retrieved 15 April 2021.
- "Mauritius Receives 100 000 Doses of Sinopharm Vaccine". allAfrica. 14 April 2021.
- "China, Africa and the Vaccine Donations". Modern Ghana. Retrieved 5 March 2021.
- Mucari M (6 March 2021). "Mozambique expects to vaccinate 16 million against coronavirus by 2022". Reuters. Retrieved 7 March 2021.
- "Khomas, Erongo first to get vaccinated". The Namibian. Archived from the original on 26 April 2021. Retrieved 17 March 2021.
- "Zimbabwe gets another 400,000 doses of China's Covid-19 vaccine". The EastAfrican. 17 March 2021. Archived from the original on 31 March 2021.
- "Covid-19 : Le Niger réceptionne 400.000 doses de vaccin SINOPHARM, un don de la Chine". Agence Nigérienne de Presse. Retrieved 21 March 2021.
- "Senegal takes delivery of China's Sinopharm vaccine". Reuters. 18 February 2021. Retrieved 19 February 2021.
- "Senegal begins covid-19 vaccination with doses from China's Sinopharm". Africanews. 23 February 2021. Retrieved 23 February 2021.
- "Sierra Leone to receive 200,000 virus vaccine doses". ewn.co.za. AFP. Retrieved 26 February 2021.
- Thomas AR (15 March 2021). "Sierra Leone's President Bio leads the way in taking COVID-19 Vaccine". SIERRA LEONE TELEGRAPH. Retrieved 15 March 2021.
- "Seychelles to start vaccinations with Chinese-made Sinopharm". AP NEWS. 8 January 2021. Retrieved 8 January 2021.
- "Seychelles rolls out COVID-19 vaccination using China's Sinopharm, says president's office". Reuters. 11 January 2021. Retrieved 18 April 2021.
- "Somalia receives vaccines from China". BusinessGhana. Retrieved 15 April 2021.
- "Somalia rolls out Sinopharm vaccines to boost fight against COVID-19". News Ghana. 15 April 2021. Retrieved 15 April 2021.
- Somalia Rolls Out Sinopharm Vaccines, 15 April 2021, retrieved 15 April 2021
- "China To Provide Sudan With 250,000 Doses Of Sinopharm Vaccine On Friday - Ambassador". UrduPoint. Retrieved 29 March 2021.
- "China-donated Sinopharm COVID-19 vaccines arrive in Sudan". dailynewsegypt.com. 28 March 2021. Retrieved 29 March 2021.
- "Covid-19: le Congo-Brazzaville reçoit des milliers de doses du vaccin chinois Sinopharm". RFI (in French). 10 March 2021. Retrieved 12 March 2021.
- Banya N (11 February 2021). "Zimbabwe purchases 600,000 Sinopharm COVID-19 vaccinations -information minister". Reuters. Retrieved 11 February 2021.
- "Zimbabwe to buy 1.2 million more COVID-19 vaccine doses from China". Reuters. 24 February 2021. Retrieved 26 February 2021.
- "China sends 100,000 coronavirus vaccines to Belarus". eng.belta.by. 19 February 2021. Retrieved 19 February 2021.
- "Finalized Contract for the Procurement of half a Million Doses of Sinopharm Vaccine". Sarajevo Times. 2 July 2021. Retrieved 3 July 2021.
- "Georgia Starts COVID-19 Vaccination with Sinopharm". Civil.ge. 4 May 2021. Retrieved 9 May 2021.
- "One mln doses of Sinopharm, Sinovac now in Georgia - mass vaccination to start on July 5". Agenda.ge. Retrieved 3 July 2021.
- "Hungary signs deal for Chinese Sinopharm's COVID-19 vaccine, first in EU". National Post. 29 January 2021. Retrieved 29 January 2021.
- "Hungary's PM Viktor Orbán vaccinated against COVID with Chinese Sinopharm vaccine". euronews. 28 February 2021.
- "Hungary takes last delivery of Sinopharm vaccine - BBJ". BBJ.hu. Retrieved 22 May 2021.
- "Emiratele Arabe Unite au donat Republicii Moldova un lot de vaccin împotriva COVID-19". TV8 (in Romanian). 13 March 2021.
- "O mie de studenți și medici-rezidenți din cadrul USMF vor fi imunizați anti-COVID cu vaccinul BBIBP-CorV, produs de către Sinopharm Beijing Institute of Biological Products". Ziarul de Gardă (in Romanian). 19 March 2021. Retrieved 19 March 2021.
- Trkanjec Z (6 May 2021). "1.5% of Montenegrin population vaccinated in one day". www.euractiv.com. Retrieved 9 May 2021.
- "North Macedonia looks to Chinese vaccine to revive program". ABC News. Retrieved 1 May 2021.
- "North Macedonia speeds up vaccinations as EU aid arrives". ABC News. Retrieved 9 May 2021.
- "Serbia receives further 500,000 doses of China's COVID-19 vaccine". seenews.com. 5 April 2021. Retrieved 7 April 2021.
- Lopez EA (16 February 2021). "Dominican Republic launches COVID-19 vaccination campaign". Reuters. Retrieved 28 February 2021.
- "Dominica: Melissa Skerrit receives the Sinopharm COVID-19 vaccine". WIC News. 4 March 2021. Retrieved 5 March 2021.
- "CITIZENS ENCOURAGED TO GET VACCINATED". Government Information Service, Government of the Commonwealth of Dominica. Archived from the original on 18 March 2021. Retrieved 5 August 2021.
- Jorgic D (10 March 2021). "Mexico leans on China after Biden rules out vaccines sharing in short term". Reuters. Retrieved 10 March 2021.
- Esposito A (26 August 2021). "Mexico grants emergency use approval to China's Sinopharm COVID-19 vaccine". Reuters. Retrieved 28 August 2021.
- "[UPDATED] 800,000 vaccines arrive in Trinidad and Tobago". Trinidad & Tobago Newsday. 13 July 2021. Retrieved 13 July 2021.
- "Barbados to get 30,000 doses of Chinese Sinopharm vaccine - PM Mottley". Barbados Today. 1 April 2021. Retrieved 1 April 2021.
- "China's Sinopharm Vaccine Arrives". Solomon Times Online. Retrieved 12 April 2021.
- "Pacific: PNG and Solomon Islands to use China's Sinopharm vaccine". ABC Radio Australia-AU. 17 May 2021. Retrieved 4 June 2021.
- "Chinese COVID-19 vaccine is in PNG". National Control Center for COVID-19. 1 July 2021.
- Biannchi W (21 February 2021). "Argentina approves Sinopharm COVID-19 vaccine for emergency use". Reuters. Retrieved 22 February 2021.
- "The Government signed a new contract with Sinopharm and ensures that 2 million doses will arrive in June". Market Research Telecast. 11 June 2021. Retrieved 15 June 2021.
- "Bolivia se apoya en China para vacunas contra el COVID-19". Associated Press. 1 July 2021. Retrieved 1 July 2021.
- Seoraj N (3 March 2021). "China-donated Sinopharm vaccine received". Guyana Chronicle. Retrieved 3 March 2021.
- "Gov't purchases 100,000 Sinopharm vaccines". Stabroek News. 9 June 2021. Retrieved 11 June 2021.
- "Peru inks deals with Sinopharm, AstraZeneca for coronavirus vaccines -president". Reuters. 6 January 2021. Retrieved 7 January 2021.
- Aquino M (27 January 2021). "Peru grants 'exceptional' approval for Sinopharm COVID-19 vaccine - government sources". Reuters. Retrieved 28 January 2021.
- Sequera V (1 March 2021). "Venezuela approves use of China's Sinopharm coronavirus vaccine". Reuters. Retrieved 2 March 2021.
- Sequera V (2 March 2021). "Venezuela receives donated coronavirus vaccine from China". Reuters. Retrieved 2 March 2021.
- Long G (18 February 2021). "Peru's political elite ensnared in 'Vacuna-gate' scandal". Financial Times. Retrieved 10 July 2021.
- "Philippines' Duterte apologises for taking unapproved China jab". BBC News. 6 May 2021. Retrieved 10 July 2021.
External links
Scholia has a profile for BBIBP-CorV (Q97154230).
- Corum J, Zimmer C (30 December 2020). "How the Sinopharm Vaccine Works". The New York Times.
| Artificial induction of immunity / Immunization: Vaccines, Vaccination, Infection, Inoculation (J07) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Development | |||||||||||
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
